General
Preferred name
cariprazine
Synonyms
CARIPRAZINE HYDROCHLORIDE ()
RGH-188 ()
RGH188 hydrochloride ()
Cariprazine HCl ()
Cariprazine (hydrochloride) ()
cariprazine hydrochloride, prolonged-release ()
RGH-188 HCL ()
VRAYLAR ()
Reagila ()
MP-214 ()
Fri-7000188 ()
GED-129 ()
Cariprazina ()
Cariprazine-d6 ()
P&D ID
PD009328
CAS
839712-12-8
1083076-69-0
1308278-67-2
Tags
available
drug
Approved by
FDA
First approval
2015
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION
Cariprazine is an atypical antipsychotic indicated for the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I; disorder.
TOXICITY
Accidental acute overdosage (48 mg/day) was reported in one patient. This patient experienced orthostasis and sedation. The patient fully recovered the same day.; Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Cariprazine is not approved for the treatment of patients with dementia-related psychosis.
DESCRIPTION
Cariprazine is an antipsychotic. Our structure was drawn from the INN record which shows stereo-chemistry for this compound. PubChem have a record only for the non-chiral molecule, with CID 11154555. The compound is liphophilic meaning that it can easily cross the blood-brain barrier, to reach its site of action .
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
21
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
47
Molecular Weight
426.2
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
1
cLogP
4.34
TPSA
38.82
Fraction CSP3
0.67
Chiral centers
0.0
Largest ring
6.0
QED
0.76
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Target
D3
D2
5-HT1A
DRD2, DRD3
MOA
Dopamine Receptor
5-HT Receptor
Dopamine D2/3 receptor partial agonist
Dopamine Receptor antagonist
Member status
member
Indication
schizophrenia
Recommended Cell Concentration
None
Source data